Skip to main content

AP32788-15-101 A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer

NCT02716116

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

Takeda Pharmaceutical Company

The purpose of this study is to learn about the amount of TAK-788 that may be given safely to individuals with non-small cell lung cancer, and how well it is tolerated. The study will also test how much TAK-788 is in your blood at different times after you have taken TAK-788. This is the first study where TAK-788 will be tested in people.

This study is currently enrolling.